*	OR T3 T4
R1	Has_value Arg1:T8 Arg2:T7	
R2	Has_value Arg1:T6 Arg2:T7	
*	OR T6 T8
R3	Has_index Arg1:T9 Arg2:T10	
R4	Has_temporal Arg1:T8 Arg2:T9	
R5	Has_temporal Arg1:T6 Arg2:T9	
R6	Has_multiplier Arg1:T12 Arg2:T11	
R7	Has_temporal Arg1:T12 Arg2:T13	
*	OR T16 T15
R8	Has_temporal Arg1:T12 Arg2:T14	
R9	Has_temporal Arg1:T12 Arg2:T16	
R10	Has_index Arg1:T20 Arg2:T21	
R11	Has_temporal Arg1:T19 Arg2:T20	
R12	Subsumes Arg1:T18 Arg2:T19	
R13	Has_value Arg1:T27 Arg2:T28	
R14	Has_temporal Arg1:T27 Arg2:T29	
R15	Has_temporal Arg1:T30 Arg2:T26	
R16	Has_index Arg1:T26 Arg2:T31	
R17	Has_qualifier Arg1:T27 Arg2:T30	
R18	Has_temporal Arg1:T32 Arg2:T33	
R19	Has_index Arg1:T33 Arg2:T36	
R20	Has_qualifier Arg1:T37 Arg2:T32	
R21	Has_value Arg1:T37 Arg2:T38	
R22	Has_qualifier Arg1:T38 Arg2:T39	
R23	Has_index Arg1:T40 Arg2:T41	
R24	Has_temporal Arg1:T37 Arg2:T40	
R25	Has_index Arg1:T43 Arg2:T45	
R26	Has_temporal Arg1:T42 Arg2:T43	
R27	Has_qualifier Arg1:T46 Arg2:T42	
R28	Has_temporal Arg1:T46 Arg2:T47	
R29	Has_multiplier Arg1:T49 Arg2:T48	
R30	Has_qualifier Arg1:T49 Arg2:T50	
R31	Subsumes Arg1:T48 Arg2:T51	
R32	AND Arg1:T49 Arg2:T52	
R33	Has_qualifier Arg1:T55 Arg2:T56	
R34	AND Arg1:T49 Arg2:T55	
R35	Has_value Arg1:T59 Arg2:T58	
R36	Subsumes Arg1:T57 Arg2:T59	
R37	Has_value Arg1:T62 Arg2:T61	
R38	AND Arg1:T71 Arg2:T72	
*	OR T63 T70 T65 T64 T71
R39	Has_temporal Arg1:T70 Arg2:T74	
R40	Has_temporal Arg1:T65 Arg2:T66	
R41	Subsumes Arg1:T67 Arg2:T68	
R42	Has_context Arg1:T64 Arg2:T67	
*	OR T77 T78
*	OR T68 T69
R43	Subsumes Arg1:T76 Arg2:T77	
R44	Has_context Arg1:T63 Arg2:T76	
R45	Has_value Arg1:T81 Arg2:T80	
R46	AND Arg1:T83 Arg2:T82	
R47	AND Arg1:T84 Arg2:T85	
R48	AND Arg1:T87 Arg2:T86	
R49	AND Arg1:T88 Arg2:T89	
*	OR T83 T84 T87 T88
R50	AND Arg1:T49 Arg2:T53	
T1	Visit 17 27	outpatient
T2	Post-eligibility 30 130	Informed consent: Subjects must give their signed and dated written informed consent to participate.
T3	Person 140 144	Male
T4	Person 148 154	female
T5	Pregnancy_considerations 156 448	Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.
T6	Person 450 453	Age
T7	Value 455 474	>=40 and <=80 years
T8	Person 478 481	age
T9	Temporal 482 494	at Screening
T10	Reference_point 485 494	Screening
T11	Multiplier 564 579	>=10 pack-years
T12	Observation 583 600	cigarette smoking
T13	Temporal 601 613	at screening
T14	Temporal 553 560	history
T15	Temporal 547 552	prior
T16	Temporal 536 543	current
T18	Condition 625 641	Previous smokers
T19	Observation 672 687	stopped smoking
T20	Temporal 688 726	for at least 6 months prior to Visit 1
T21	Reference_point 719 726	Visit 1
T23	Parsing_Error 729 749	Airflow Obstruction:
T24	Drug 781 790	albuterol
T25	Drug 791 801	salbutamol
T26	Temporal 776 801	post-albuterol/salbutamol
T27	Measurement 802 878	forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio
T28	Value 882 888	<=0.70
T29	Temporal 889 901	at Screening
T30	Qualifier 776 801	post-albuterol/salbutamol
T31	Reference_point 781 801	albuterol/salbutamol
T32	Qualifier 939 964	post-albuterol/salbutamol
T33	Temporal 939 964	post-albuterol/salbutamol
T34	Drug 944 953	albuterol
T35	Drug 954 964	salbutamol
T36	Reference_point 944 964	albuterol/salbutamol
T37	Measurement 965 969	FEV1
T38	Value 970 1011	>=50 and <=70% of predicted normal values
T39	Qualifier 1023 1059	using NHANES III reference equations
T40	Temporal 1095 1107	at Screening
T41	Reference_point 1098 1107	Screening
T42	Qualifier 1120 1139	Post-bronchodilator
T43	Temporal 1120 1139	Post-bronchodilator
T44	Drug 1125 1139	bronchodilator
T45	Reference_point 1125 1139	bronchodilator
T46	Procedure 1140 1150	spirometry
T47	Temporal 1169 1199	approximately 15 minutes after
T48	Multiplier 1234 1235	4
T49	Procedure 1236 1247	inhalations
T50	Qualifier 1216 1233	self-administered
T51	Multiplier 1261 1267	400mcg
T52	Drug 1272 1281	albuterol
T53	Drug 1282 1292	salbutamol
T55	Procedure 1299 1326	metered dose inhaler (MDI )
T56	Qualifier 1326 1355	with a valved-holding chamber
T57	Condition 1431 1447	Symptoms of COPD
T58	Value 1463 1480	score 2 or higher
T59	Measurement 1488 1535	modified Medical Research Council Dyspnea scale
T60	Parsing_Error 1547 1570	Cardiovascular disease:
T61	Value 1585 1596	>= 40 years
T62	Person 1600 1603	age
T63	Condition 1688 1717	coronary artery disease (CAD)
T64	Condition 1774 1807	peripheral vascular disease (PVD)
T65	Condition 1817 1823	stroke
T66	Temporal 1808 1816	Previous
T67	Observation 1718 1729	Established
T68	Observation 1739 1753	clinical signs
T69	Procedure 1757 1772	imaging studies
T70	Condition 1833 1835	MI
T71	Condition 1836 1853	Diabetes mellitus
T72	Condition 1859 1879	target organ disease
T73	Parsing_Error 1880 1882	OR
T74	Temporal 1824 1832	Previous
T76	Observation 1632 1643	Established
T77	Observation 1653 1667	clinical signs
T78	Procedure 1671 1686	imaging studies
T80	Value 1897 1907	>=60 years
T81	Person 1911 1914	age
T82	Condition 1959 1979	hypercholesterolemia
T83	Procedure 1947 1979	treated for hypercholesterolemia
T84	Procedure 1986 2010	treated for hypertension
T85	Condition 1998 2010	hypertension
T86	Condition 2029 2046	diabetes mellitus
T87	Procedure 2017 2046	treated for diabetes mellitus
T88	Procedure 2053 2092	treated for peripheral vascular disease
T89	Condition 2065 2092	peripheral vascular disease
